Mirae Asset Global ETFs Holdings
BCRX icon

Mirae Asset Global ETFs Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
138,083
+6,923
+5% +$62.6K ﹤0.01% 1467
2026
Q1 		$1.25M Buy
131,160
+11,593
+10% +$90K ﹤0.01% 1413
2025
Q4 		$929K Buy
119,567
+3,366
+3% +$24.3K ﹤0.01% 1562
2025
Q3 		$881K Sell
116,201
-13,303
-10% -$111K ﹤0.01% 1558
2025
Q2 		$1.17M Sell
129,504
-5,810
-4% -$54.1K ﹤0.01% 1376
2025
Q1 		$1.02M Buy
135,314
+8,517
+7% +$68.7K ﹤0.01% 1488
2024
Q4 		$954K Sell
126,797
-929
-0.7% -$7.05K ﹤0.01% 1571
2024
Q3 		$971K Buy
127,726
+14,199
+13% +$108K ﹤0.01% 1555
2024
Q2 		$700K Buy
+113,527
New +$626K ﹤0.01% 1650

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's BCRX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its BioCryst Pharmaceuticals (BCRX) stake by 5.3% in Q2 2026, buying an estimated $62.6K and bringing the position to 138,083 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

Mirae Asset Global ETFs Holdings first reported a position in BCRX in Q2 2024 and has held it in 9 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 138,083 shares of BioCryst Pharmaceuticals worth $1.37M as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 6,923 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $62.6K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1467 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.